Tags

Type your tag names separated by a space and hit enter

Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K.
Cancer Immunol Immunother. 1995 Dec; 41(6):389-96.CI

Abstract

Polysaccharide K (PSK) is a biological response modifier used for adjuvant immunotherapy of malignant diseases. We studied the potential applicability of PSK for preventing tumor progression using an experimental model of murine lymphoma. Mice inoculated with the radiation leukemia virus (RadLV) develop thymic lymphomas after a latency of 3-6 months. However, 2 weeks after virus inoculation, prelymphoma cells can already be detected in the thymus. We found that PSK treatment induced hyperresponsiveness to concanavalin A and heightened production of interleukin-2 (IL-2) and IL-4 in spleen cells of both control and prelymphoma mice. The response was transient and was accompanied with a dominant usage of T cells expressing V beta 8, but other T cell subsets were also stimulated by PSK. T lymphoma cells expressing V beta 8.2 underwent apoptosis when incubated with PSK. Treatment of RadLV-inoculated mice with PSK delayed the onset of overt lymphoma (and mortality) but could not protect the mice from the disease. Combined treatment with PSK and a RadLV-specific immunotoxin prevented synergistically the progression of the prelymphoma cells to frank lymphoma. The results suggest that PSK contains a superantigen-like component that selectively activates V beta 8+ T cells. Its administration prelymphoma mice interfered with the process of lymphoma progression.

Authors+Show Affiliations

Yefenof E
Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Gafanovitch I
No affiliation info available
Oron E
No affiliation info available
Bar M
No affiliation info available
Klein E
No affiliation info available

MeSH

Adjuvants, ImmunologicAge of OnsetAnimalsAntigen PresentationApoptosisFemaleGene Rearrangement, beta-Chain T-Cell Antigen ReceptorImmunotherapyLymphocyte ActivationLymphocyte DepletionLymphomaMiceMice, Inbred C57BLPrecancerous ConditionsProteoglycansRadiation Leukemia VirusReceptors, Antigen, T-Cell, alpha-betaRetroviridae InfectionsSpecific Pathogen-Free OrganismsSpleenT-Lymphocyte SubsetsThymus NeoplasmsTumor Virus Infections

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8635197

Citation

Yefenof, E, et al. "Prophylactic Intervention in Radiation-leukemia-virus-induced Murine Lymphoma By the Biological Response Modifier Polysaccharide K." Cancer Immunology, Immunotherapy : CII, vol. 41, no. 6, 1995, pp. 389-96.
Yefenof E, Gafanovitch I, Oron E, et al. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother. 1995;41(6):389-96.
Yefenof, E., Gafanovitch, I., Oron, E., Bar, M., & Klein, E. (1995). Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunology, Immunotherapy : CII, 41(6), 389-96.
Yefenof E, et al. Prophylactic Intervention in Radiation-leukemia-virus-induced Murine Lymphoma By the Biological Response Modifier Polysaccharide K. Cancer Immunol Immunother. 1995;41(6):389-96. PubMed PMID: 8635197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. AU - Yefenof,E, AU - Gafanovitch,I, AU - Oron,E, AU - Bar,M, AU - Klein,E, PY - 1995/12/1/pubmed PY - 1995/12/1/medline PY - 1995/12/1/entrez SP - 389 EP - 96 JF - Cancer immunology, immunotherapy : CII JO - Cancer Immunol Immunother VL - 41 IS - 6 N2 - Polysaccharide K (PSK) is a biological response modifier used for adjuvant immunotherapy of malignant diseases. We studied the potential applicability of PSK for preventing tumor progression using an experimental model of murine lymphoma. Mice inoculated with the radiation leukemia virus (RadLV) develop thymic lymphomas after a latency of 3-6 months. However, 2 weeks after virus inoculation, prelymphoma cells can already be detected in the thymus. We found that PSK treatment induced hyperresponsiveness to concanavalin A and heightened production of interleukin-2 (IL-2) and IL-4 in spleen cells of both control and prelymphoma mice. The response was transient and was accompanied with a dominant usage of T cells expressing V beta 8, but other T cell subsets were also stimulated by PSK. T lymphoma cells expressing V beta 8.2 underwent apoptosis when incubated with PSK. Treatment of RadLV-inoculated mice with PSK delayed the onset of overt lymphoma (and mortality) but could not protect the mice from the disease. Combined treatment with PSK and a RadLV-specific immunotoxin prevented synergistically the progression of the prelymphoma cells to frank lymphoma. The results suggest that PSK contains a superantigen-like component that selectively activates V beta 8+ T cells. Its administration prelymphoma mice interfered with the process of lymphoma progression. SN - 0340-7004 UR - https://www.unboundmedicine.com/medline/citation/8635197/Prophylactic_intervention_in_radiation_leukemia_virus_induced_murine_lymphoma_by_the_biological_response_modifier_polysaccharide_K_ L2 - https://medlineplus.gov/thymuscancer.html DB - PRIME DP - Unbound Medicine ER -